Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
vendredi, octobre 02
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Roivant Sciences Ltd
ROIV
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$35.72
0.22
0.62%
Dern. MÀJ: Oct 2, 4:03 PM
$35.68
0.18
0.51%
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Privacy Manager
Roivant Sciences Financials
Roivant Sciences (ROIV) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Roivant Sciences Q1 Adj. EPS $(0.34) Misses $(0.32) Estimate, Sales $1.442M Miss $2.057M Estimate
Roivant Sciences (NASDAQ:ROIV) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.32) by 6.25 percent. This is a 36 percent decrease over losses of $(0.25) per share from
Benzinga Newsdesk
S&P 500 Rebounds Ahead Of Nvidia's Print, Oil Sinks 5% On Iran Truce Hopes: Stock Market Today
U.S. stocks halt a three-day slide as oil tumbles 5% on revived Iran truce hopes, easing inflation fears ahead of Nvidia's results after the close.
Piero Cingari
Earnings Scheduled For May 20, 2026
Benzinga Insights
PRO
Roivant Sciences Q4 Adj. EPS $(0.27) Beats $(0.34) Estimate
Benzinga Newsdesk
PRO
Roivant Sciences Q4 Sales $2.520M Miss $3.820M Estimate
Benzinga Newsdesk
Roivant Stock Soars On Experimental Skin Drug Delivering 100% Response - Why It Matters
Roivant shares surged after its skin disease drug brepocitinib showed strong Phase 2 results, with high response rates, early benefits, and no serious safety issues.
Vandana Singh
